Hikma Pharmaceuticals PLC · LSE:HIK
Hikma Pharmaceuticals — Investor Presentation
15 slides from Hikma Pharmaceuticals's investor presentation
Slide 1: AIKMB
AIKMB Quality
Slide 2: US Injectables
US Injectables AIK. || US market overview || Our US Injectables business today || Key growth drivers for our US Injectables business
Slide 3: The US Injectables market is large and growing
The US Injectables market is large and growing US Injectables sales by value ($bn) $bn 100 90 wo 70 60 50 40 30 Generic ‘07-11 CAGR 25.0% —" 2007 2008 2008 2010 Branded Branded Generic =Generic Source : IMS Health August 2012 US Injectables sales by volume (billion eaches) 30 254 00 Generic ‘07-11 C
Slide 4: Our US Injectables business today
Our US Injectables business today AIKM. US Injectables — Total products marketed Market share of DEA controlled products (units) 60 56 100% 90% | 50 BOS 70% 40 8 6056 30 50% 40% 20 30% 20% 10 = | we 10% ° go ot 2005 = «2007-2008» 200820102011 = # # 2 g @ z #8 = 6¢ @ 3g & & 5 2 5 B - f ge i = 2 3 3 8
Slide 5: Our strong market position
million eaches Our strong market position A AIKMA US generic Injectables market share Generic injectable suppliers, by marketed products 180 112 32.5% 105 160 + 120 - 69 100 + —— 86 16.3% 168.3% 52 “7 43 6.9% 4.1% ; 19% 1 3% 1.2% 1.1% 1.0% a . 7 : e y z 6 -- \ 1% 4.0% 3.8% Lil: a 2 S zs 3 2 £ & uy B
Slide 6: Strong growth driven by the continued launch of new products
Strong growth driven by the continued launch of new products FN US Injectables revenue growth from 2006-2011 162.2 Organic growth CAGR (06-11) 21.1% 2 _— —_— 249 7 19.3 47.0 2006 2007 2008 2008 2010 2011 MMM US Injectables excluding MSI @/ msi
Slide 7: Well established relationships with key customers
Well established relationships with key customers > Strong positions with all five major GPOs » Growing scale provides better negotiating power >» Good relationships will help drive market share gains Hikma’s US Injectables revenue breakdown by customer (%) - IHNs/ Hospitals - direct (2%) Wholesaler
Slide 8: Building stronger ties with GPOs through broad portfolio and reliability of supply
Building stronger ties with GPOs through broad portfolio and reliability of supply AAmerinet? EP vEALTHTRUST
Slide 9: Developing stronger relationships with wholesalers
Developing stronger relationships with wholesalers AIKMA __ AmerisourceBergerr MCKESSON CardinalHealth
Slide 10: Increasing our direct sales to Integrated Hospital Networks
Increasing our direct sales to Integrated Hospital Networks Fasc Mg Oi: : | UPMC Cleveland Clinic University of Pittsburgh Catholic Healthcare West Medical Center SI TARP San Diego's Health Care Leader Ww INOVA Intermountain Healthcare BAYLOR foley fr Gf ~ Health Care System oD Scripps wy I IIGHMARK
Slide 11: Broad sales coverage will support our growing product portfolio
Broad sales coverage will support our growing product portfolio FN > Well established sales team with coverage across the US market > Potential to leverage existing reps as our product portfolio expands © Puerto Rico
Slide 12: Solid foundation for continued revenue growth
Solid foundation for continued revenue growth For illustrative purposes only US Injectables revenue | a 2010 2011 2012 MMOS Injectables revenue Growth Drivers ME Market Conditions ME New Products " 2013 AIKMIN. Growth in 2011 and 2012 was driven by: — MSI portfolio optimisation — New product launche
Slide 13: More differentiated products will drive future growth
More differentiated products will drive future growth > = Acquiring new products — Sodium ferrous gluconate — Purchased ANDA for $16 million - Only approved generic alternative » Partnering to develop our pipeline — Argatroban — Successful outcome to patent challenge — Gives confidence in our model
Slide 14: Increased capacity will provide flexibility to benefit from ongoing supply shortages
Increased capacity will provide flexibility to benefit from ongoing supply shortages 96 products are on the short supply list * Jard currently markets 14 of these products West: Aifentanil injection Amigacin Inection Amine Acio Products Ammonium Chloride injection Ammonul Injection Aguasal A Atracur
Slide 15: Well positioned to grow our US Injectables business
Well positioned to grow our US Injectables business OUR GLOBAI RATE STRATEGIC PRIORITIES IN EACH REGION >» Growing global generic us injectables sales - Increasing R&D — Focusing on higher value, more differentiated products — Pursuing new in- license arrangements — Product acquisitions >» Increasin